BridgeBio Pharma’s Attruby (Aprovi) generated $222 million in U.S. net product revenue in the most recent quarter, with royalty income from Bayer’s BEYONTTRA adding about $15 million, marking a 23% sequential increase. The drug’s near-term sales projections range from $25 million to $30 million per quarter, with annualized revenue nearing $250 million—a threshold typically required to qualify as a blockbuster. Peak-year sales guidance remains at $4 billion, with potential for additional upside if regulatory milestones are achieved.
BridgeBio Pharma’s Attruby Sales Hit $222M, Eyes $4B Peak Potential
Attruby’s U.S. revenue growth of 23% in the latest quarter underscores its trajectory toward blockbuster status, while financial losses stabilize at $100M quarterly.
PA
Priya Anand · Equities & Earnings Desk · 16 Sept 2026 · 11:50 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
